Clinical Trials Logo

Chronic Migraine clinical trials

View clinical trials related to Chronic Migraine.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05858801 Active, not recruiting - Chronic Migraine Clinical Trials

First Evaluation of a Craniofacial Peripheral Nerve Stimulation System in Chronic Migraine

RELIEF
Start date: May 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the safe use of the novel cranio-facial peripheral nerve stimulator (PNS) System in subjects with chronic migraine. This is a single-centre, open label, prospective, early feasibility study to collect initial clinical data on the PNS System for the treatment of chronic migraine.

NCT ID: NCT04686136 Active, not recruiting - Chronic Migraine Clinical Trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Start date: February 19, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

NCT ID: NCT04437433 Active, not recruiting - Chronic Migraine Clinical Trials

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Start date: June 18, 2020
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic or episodic migraine.

NCT ID: NCT04271202 Active, not recruiting - Chronic Migraine Clinical Trials

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Start date: July 29, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention. Specifically, the protocol will allow the investigators to determine whether the main site of action of this novel and recently-approved class of migraine prophylactic drugs act inside or outside the brain and if so, where.